This journal offers authors two options (open access or subscription) to publish research

Messenger RNA vaccines against SARS-CoV-2

Open ArchivePublished:January 13, 2021DOI:


      The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF.


        • Jackson L.A.
        • Anderson E.J.
        • Rouphael N.G.
        • Roberts P.C.
        • Makhene M.
        • Coler R.N.
        • McCullough M.P.
        • Chappell J.D.
        • Denison M.R.
        • Stevens L.J.
        • et al.
        • mRNA-1273 Study Group
        An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
        N. Engl. J. Med. 2020; 383: 1920-1931
        • Polack F.P.
        • Thomas S.J.
        • Kitchin N.
        • Absalon J.
        • Gurtman A.
        • Lockhart S.
        • Perez J.L.
        • Pérez Marc G.
        • Moreira E.D.
        • Zerbini C.
        • et al.
        • C4591001 Clinical Trial Group
        Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
        N. Engl. J. Med. 2020; 383: 2603-2615

      Cell Press Coronavirus Resource Hub

      Related Resources
      Access free COVID-19 content as it appears in Cell Press journals.